Baseline data of each group (mean±standard deviation)/n (%)/(M(IQR)). by Na Wang (193263)

Subjects:

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel ef... by Takafira Mduluza (39754)

Decreasing oxygen saturation with corresponding levels of NLR and D-dimer for understanding the interplay of inflammation. by Narendran Gopalan (110148)

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

Subjects:

Effects of s-ketamine and midazolam on respiratory parameters. by Oscar F. C. van den Bosch (22184246)

Subjects:

Flow chart of the study participants. by Oscar F. C. van den Bosch (22184246)

Subjects:

S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Va... by Sonsawan Sangprasert (22772538)

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

“…In both group, the DPSI also decreased significantly one month post-treatment compared to before and after treatment (P = 0.040 and P = 0.018, respectively). …”

Relevant follow-up evaluation indicators after operation (mean±standard deviation)/n (%). by Na Wang (193263)

Subjects:

Mean values of physical parameters of rock samples. by Dengke Yang (842532)

Subjects:

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. by William C. Barley (8915282)

Subjects:

Distribution of continuous variables of all 3 visits (visit 1 = day 0, visit 2 = day 35, and visit 3 = day 70) of the PCSO-524 group and the placebo group. Results are shown as mea... by Nattapon Riengvirodkij (11268720)

Subjects:

Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS)... by Takafira Mduluza (39754)

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Clinical and demographic characteristics of the participants. by María Benito-de-Pedro (22057468)

Subjects:

Mean conidial viability of <i>Beauveria</i> and <i>Metarhizium</i> isolates. by Aime Cheoh Enoh (20141758)

Subjects: